Free shipping on antibody orders delivered to Canada

Blog

     The cellular microenvironment can modulate intracellular pathways, these interactions can occur in normal or physiopathological conditions.

lire la suite
September 27th 2018 - MédiMabs is presenting StabiliMABS

     StabiliMABS is a two part option you can apply on any custom hybridoma project. We would first apply StabiliMABS-1 on early positive clones (up to 100) and harvest some supernatant (250µL) for you to test in your application. We then continue the hybridoma normal process and send you the supernatant of the clones obtained through the standard procedure (up to 10).

lire la suite
September 27th 2018 - EGFRs in cancer

     Epithelial Growth Factor Receptors are a family of receptor tyrosine kinase well studied for their role in cancer. (1) They have been widely used as biomarkers and therapeutic targets.

lire la suite
September 19th 2018 - Neurosciences

     Research on neurodegenerative disease has always been important at MédiMabs. Partly because two of our founders have dedicated their career to this field of research and partly because we are all touched by these at different levels in our personal life. We always feel proud and implicated when top researchers in neuroscience come to us to develop their new research tools or use our products.

lire la suite
September 19th 2018 - CRCHUM show October 11th 2018

     It will be our pleasure to meet you at our booth during the Biotech-connect event on October 11th at the CRCHUM in Montréal. We will be ready to answer your questions and help you in your research projects.

lire la suite
September 19th 2018 - SOD1 and ALS

     The discovery of the implication of SOD1 mutants in familial ALS has turned 25 this year.(1) ALS was discovered more than 100 years ago by the French neurologist Jean-Martin Charcot.

lire la suite

FGFR are a family of transmembrane tyrosine kinase receptors widely conserved and involved in various physiological response.(1) The growing research interest over the past decades have led to many new discoveries especially in the field of cancer research.

lire la suite
September 10th 2018 - MédiMabs - CCAB series launch

MédiMabs is pleased to announce you that we have set an official agreement with the CCAB for the commercialization of their research reagents under the brand MédiMabs - CCAB series. We are starting with 19 new antibodies against various cell surface targets + an antibody panel against 6 different FGFR isoforms. All of these high quality antibodies were developed by CCAB on their phage display platform.

lire la suite
September 06th 2018 - MaRS show on September 13th 2018

MaRS research center is public and private initiative with the goal of filling the gap between academic research and private commercialization. It will be our pleasure to meet you at our booth during the Biotech-connect event on September 13th. We will be ready to answer your questions and help you in your research projects.

lire la suite
August 10th 2018 - Website launch

MédiMabs has undergone recent changes its website in aims of providing users a richer online experience. There are many new and exciting features that we wish to share with you. We hope you can benefit from them! Click here

The catalogue searchability has been updated and it now ensures you to find the perfect products easily for your experiments. Order processing has been optimized to your needs and we now can automatically generate official quote and pay them online using an official purchase orders.

lire la suite